patent.fyi
Applications  /  US 2026/0355195
United States Patent Application Publication

US 2026/0355195 A1

Published
Nov 12, 2026
Filed
Oct 17, 2023
Earliest date on the face
Oct 17, 2022
Classification
A61K 31/506
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

No entries.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Immune timing in implant material tests

A medical materials test places sterile implant coupons in culture inserts suspended above lymphocyte and monocyte cocultures. Matched wells contain empty inserts and receive the same medium changes. At successive time points, flow cytometry measures intracellular pH, activation markers, and viability in the lymphocyte population. The resulting time series compares the onset, peak, and recovery of the cellular response across coupon materials.

Component substitution

Fluorescent readout of intracellular acidity

A fluorescence plate reader and the ratiometric dye BCECF replace an intracellular pH estimate inferred from metabolic activity. Near-neutral extracellular medium surrounds dye-loaded cells during measurement, and the reader records emission at 535 nm after excitation at 440 and 490 nm. Parallel calibration wells contain high-potassium buffers of known pH and nigericin to equilibrate intracellular and extracellular pH. A calibration curve converts the 490-to-440 nm fluorescence ratio to intracellular pH.

Parameter or scale variation

Dense sampling of lymphocyte activation

A 96-well plate holds 18 wells of purified T cells for stimulation and 18 matched wells for unstimulated controls. Each well starts with 100,000 cells in 200 microliters of medium, and the stimulated wells receive antibodies against CD3 and CD28 at time zero. Three wells from each condition are harvested at each of six time points spanning 0, 2, 6, 12, 24, and 48 hours. Flow cytometry measures intracellular pH and surface CD69 at each time point to track the timing of early activation.

Dose matrix for tumor spheroid acidification

A 96-well low-attachment plate holds tumor cell spheroids in triplicate across a 5-by-5 concentration matrix of a glycolysis inhibitor and a lactate transport inhibitor. Each axis has a vehicle-only level and four nonzero concentrations, so the matrix includes the vehicle control, both single-agent series, and all pairwise combinations. A calibrated ratiometric dye measures intracellular pH after 2 and 6 hours of exposure. A live-cell stain and a membrane-impermeant dye record viability at 24 hours for comparison with the earlier pH measurements.

Combination with existing systems

Topical ph testing on epidermal inserts

A reconstructed human epidermis sits on a porous insert above a reservoir of buffered culture medium. A gel containing a citrate buffer covers the exposed epidermal surface, and parallel inserts receive the gel base alone. A flat-surface electrode measures surface pH before application and after gel removal, while a calibrated fluorescent dye measures intracellular pH in the viable layers. Electrical resistance across the insert records changes in barrier integrity during exposure and recovery.

Automated or data-driven variant

Automated staging from serial cell measurements

A plate handler moves replicate lymphocyte cultures from an incubator to an automated flow cytometer on a fixed schedule. Software gates viable singlet lymphocytes and extracts median intracellular pH, median CD69 fluorescence, and the fraction of cells expressing a proliferation marker. A hidden Markov model fitted to reference time courses uses those measurements and their order to label resting, early activation, proliferation, and recovery stages. The software records each stage assignment with its probability and flags samples with too few viable lymphocytes for analysis.

Cite aspatent.fyi, US 2026/0355195 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355195/, SHA-256 f75ca69884e8bf73c1ca9136ab96725a76e6eef547fac8cf1da5ac9d99d6abc2
First published
Permanent addresshttps://patent.fyi/US20260355195/
Content fingerprint (SHA-256)f75ca69884e8bf73c1ca9136ab96725a76e6eef547fac8cf1da5ac9d99d6abc2
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi